JPRN-jRCT2080224763已完成2 期
Phase II study of Durvalumab (MEDI4736) Plus Concurrent Radiation Therapy in Advanced Localized NSCLC Patients (Dolphin study: WJOG11619L Investigator-Initiated Clinical Trial)
Motoko Tachihara (Coordinating Investigator)0 个研究点目标入组 35 人开始时间: 2019年7月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(Inclusion criteria for 1st registration)
- •1.Patients with a histologically confirmed diagnosis of NSCLC
- •2.Patients with measurable disease as defined by the RECIST version 1.1
- •3.Patients who were not previously treated with chemotherapy for ling cancer
- •4.ECOG PS 0 or 1
- •(Inclusion criteria for 2nd registration)
- •1.PD-L1 expression >=1% (SP263)
- •2.Patients who are confirmed to be stage IIIA/IIIB/IIIC clinically according to General Rule for Clinical and Pathological Record of Ling cancer (the 8th edition)
- •3.Possible to start radiation therapy based on the protocol in this study.
排除标准
- •1.Patients with active other cancers except for NSCLC
- •2.Patients with a past or current history of interstitial lung disease evident on CT scans,
- •3.Patients with a history of immune antibody therapy and other immunotherapy
- •4.Pregnant women, lactating women, women who may be pregnant at present.
研究者
相似试验
进行中（未招募）
1 期
A phase Ib/II study of Durvalumab (MEDI4736) combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)EUCTR2016-003998-17-BEGrand Hôpital de Charleroi57
招募中
2 期
Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial)2024-515240-24-00Grupo Espanol Multidisciplinar En Cancer Digestivo60
进行中（未招募）
2 期
A Phase II study of Durvalumab (MEDI4736) plus carboplatin and etoposide in elderly patients with extensive-stage small-cell lung cancerextensive-stage small cell lung cancerJPRN-jRCTs071210050Koichi Azuma40
进行中（未招募）
1 期
Durvalumab plus tremelimumab for progressive, refractory advanced thyroid carcinomaAdvanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary,follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC).Advanced medullary thyroid carcinoma (MTC)Advanced anaplastic thyroid cancer (ATC)MedDRA version: 20.0Level: PTClassification code 10076603Term: Poorly differentiated thyroid carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10002240Term: Anaplastic thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10016935Term: Follicular thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10071027Term: Thyroid cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10071028Term: Thyroid cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001066-42-ESSpanish Group of Neuroendocrine Tumors (GETNE)84
进行中（未招募）
1 期
Durvalumab plus Tremelimumab for gastrointestinal-pancreatic or advanced pulmonar tumoursAdvanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin.MedDRA version: 19.1Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 100000004864EUCTR2016-002858-20-ESGETNE (Grupo Español de Tumores Neuroendocrinos)